Strategic Partnerships Potential sales opportunities through licensing or co-development partnerships with large biopharma companies seeking pediatric or rare-disease programs, leveraging Aevi's recent Kyowa Kirin collaboration and focus on genetic therapies.

Monoclonal Focus Target interest in CERC-002 monoclonal antibody programs for collaboration or out-licensing opportunities, given the expanded rights with Kyowa Kirin and the ongoing pursuit of indications across pediatric populations.

Clinical Milestones Position Aevi as a partner for milestone-driven deals tied to clinical and regulatory progress, given prior CVRs and all-stock acquisitions that highlight value tied to development milestones.

Emerging Markets Leverage Aevi's genomics-driven approach to appeal to investors or partners seeking precision medicine in rare or genetically defined diseases, aligning with mid- to late-stage collaboration opportunities.

Financial Signals Despite small revenue, Aevi’s $79M funding and strategic acquisitions suggest readiness for partnership discussions around co-funding pivotal trials or accelerated development programs.